Alkermes (ALKS) Net Margin (2010 - 2026)

Alkermes (ALKS) posted quarterly Net Margin of 0.11% for Q2 2026, up 100.62% quarter-over-quarter from 16.93% in Q1 2026.

Alkermes (ALKS) Net Margin (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Net Margin for 17 consecutive years, with 0.11% the latest figure, recorded in Q2 2026.

In Q2 2026, Net Margin changed N/A year-over-year to 0.11%; the TTM figure through Jun 2026 stood at 1.0% (down 104.0% YoY), while the FY2025 annual figure was 16.37%, up 1675.0% from the prior year.
Net Margin advanced to 0.11% in Q2 2026 per ALKS's latest filing, from 16.93% in the prior quarter.
Across five years, Net Margin topped out at 28.79% in Q4 2022 and bottomed at 1999.19% in Q3 2022.
Historically, Net Margin has averaged 198.19% across 5 years, with a median of 6.82% in 2023.
Annual changes were most pronounced in 2022 — Net Margin tumbled 198933 bps — and 2023, when it soared 198728 bps.
Alkermes' Net Margin stood at 28.79% in 2022, then plunged by 138 bps to 10.82% in 2023, then jumped by 102 bps to 0.26% in 2024, then surged by 4831 bps to 12.84% in 2025, then plunged by 99 bps to 0.11% in 2026.
Business Quant data shows ALKS's Net Margin at 0.11% in Q2 2026, 16.93% in Q1 2026, and 12.84% in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	-13.91%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	9.28%
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	42.51%
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	-3.16%
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	15.06%
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	3.95%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	0.11%

Download Data